- Home
- GCI vs CSTL Comparison
GCI vs CSTL Comparison
Compare GCI & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCI
- CSTL
- Stock Information
- Founded
- GCI 1997
- CSTL 2007
- Country
- GCI United States
- CSTL United States
- Employees
- GCI N/A
- CSTL N/A
- Industry
- GCI Newspapers/Magazines
- CSTL Medical Specialities
- Sector
- GCI Consumer Discretionary
- CSTL Health Care
- Exchange
- GCI Nasdaq
- CSTL Nasdaq
- Market Cap
- GCI 509.6M
- CSTL 456.2M
- IPO Year
- GCI N/A
- CSTL 2019
- Fundamental
- Price
- GCI $3.84
- CSTL $20.00
- Analyst Decision
- GCI Buy
- CSTL Strong Buy
- Analyst Count
- GCI 3
- CSTL 6
- Target Price
- GCI $5.70
- CSTL $37.67
- AVG Volume (30 Days)
- GCI 1.6M
- CSTL 439.2K
- Earning Date
- GCI 07-31-2025
- CSTL 08-04-2025
- Dividend Yield
- GCI N/A
- CSTL N/A
- EPS Growth
- GCI N/A
- CSTL N/A
- EPS
- GCI 0.36
- CSTL N/A
- Revenue
- GCI $2,445,127,000.00
- CSTL $347,083,000.00
- Revenue This Year
- GCI N/A
- CSTL N/A
- Revenue Next Year
- GCI N/A
- CSTL $1.36
- P/E Ratio
- GCI $10.38
- CSTL N/A
- Revenue Growth
- GCI N/A
- CSTL 38.43
- 52 Week Low
- GCI $2.55
- CSTL $15.45
- 52 Week High
- GCI $5.93
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- GCI 60.10
- CSTL 59.84
- Support Level
- GCI $3.57
- CSTL $19.21
- Resistance Level
- GCI $3.84
- CSTL $20.63
- Average True Range (ATR)
- GCI 0.15
- CSTL 0.67
- MACD
- GCI 0.03
- CSTL 0.01
- Stochastic Oscillator
- GCI 84.78
- CSTL 75.95
About GCI Gannett Co. Inc.
Gannett Co Inc is a digital newspaper company providing local media and marketing solutions in the U.S. The group operates in three segments, Domestic Gannett Media, Newsquest, and Digital Marketing Solutions. The majority of revenue is from the Domestic Gannett Media segment. The company's brands include USA TODAY and more than 250 daily newspapers as well as digital marketing services companies, including ReachLocal, WordStream, and others. The company produces more than 350 annual events, such as themed expos. The company also operates in the U.K. through the U.K. media company Newsquest, providing more than 150 local media brands.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.